Artificial Pancreas: First Clinical Trials in Argentina 1 1Financial support from Nuria/Cellex Foundations and the Center for Diabetes Technology, University of Virginia.

SÁNCHEZ-PEÑA, R.; COLMEGNA, P.; GROSEMBACHER, L.; GARELLI, F.; BRETON, M.; DE BATTISTA, H.; BELLOSO, W.H.; CAMPOS-NÁNEZ, E.; SIMONOVICH, V.; BERUTO, V.; SCIBONA, P.; CHERNAVVSKY, D.

IFAC-PapersOnLine

Elsevier

Lugar: Amsterdam; Año: 2017 vol. 50 p. 7731 - 7736

2405-8963

The rst clinical trials using an Articial Pancreas (AP) in Latin America have beendened in 2 stages. The rst stage was carried out in November 2016 with the UVA controller(developed by the Center for Diabetes Technology and already clinically tested), and the secondwill be performed during the rst semester of 2017 with the ARG (Automatic Regulation ofGlucose) algorithm (developed by ITBA, UNQ, and UNLP in Argentina). Both tests are basedon the DiAs (Diabetes Assistant) from the UVA, and are performed in the HIBA on 5 patientswith Type 1 Diabetes Mellitus (T1DM), for 36 hours. For the rst stage, Open-Loop (OL)insulin boluses were applied before meals and patient´s physical activity was included. On theother hand, for the second stage, patients will not be involved in physical activity, but no OLinsulin boluses will be injected before meals. In this work, experimental results from the rststage with the UVA controller, and preliminary results with the ARG control algorithm testedon the UVA/Padova simulator are presented. Due to the nal paper deadline, the experimentalresults from the second stage are not included here, but will be presented at the IFAC WorldCongress.